Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Schrödinger sells physics-based software that predicts how molecules will behave, and uses that same technology to discover and develop its own drugs.
Schrödinger sits at a strange crossroads: it is both a software company and a drug company. Its software lets chemists and materials scientists test molecules inside a computer before anyone touches a beaker or a lab bench. Instead of guessing which compound might work as a medicine or a new battery material, researchers can run physics-based simulations to predict how it will behave — how strongly it will bind to a target, whether it will be stable, and whether it is likely to be toxic.
The core of it is a physics engine the company calls its computational platform. From that platform it sells software licenses to big drugmakers and materials companies, and it also runs a drug discovery business of its own. For partners, it takes on discovery projects and earns milestones and royalties if things work out. For itself, it pushes its own molecules through the pipeline. Wall Street, and the company itself, treat the software side as the steady business: it is subscription and license revenue that repeats year after year, and it is by far the more reliable part of the story. The drug side is the lottery ticket. Schrödinger has taken its own programs into clinical trials, which is expensive and risky, and it has struck deals with large pharma companies who pay for its discovery engine and then pay again if it produces a winner. The software customers choose Schrödinger because predicting, say, whether a molecule will fit into a protein pocket is genuinely hard, and the company has built one of the few platforms that large pharma trusts enough to use. Its main competition is really two things: rival simulation software, and the old-fashioned alternative of just running lots of lab experiments and hoping. The company is based in New York, went public in early 2020, and its shares have been a roller coaster that mostly tracks enthusiasm for hot sectors rather than the steady software business underneath. The thing to watch is the split: the software business is a real, repeatable product, while the drug pipeline is a bet that its own technology can produce medicines worth far more than the software ever will. Schrödinger is, quite literally, betting that it can eat its own cooking.
There is one more twist worth knowing. Schrödinger is led by its founder, Ramy Farid, who came from academia, and the company's investor base has included Bill Gates' private investment firm — a useful signal that serious people believe the physics approach can matter. But belief is not the same as proof. The software makes money today; the drug pipeline is a promise that compounds the risk. For the curious 15-year-old version: imagine building a super-accurate flight simulator, selling time on it to airplane makers, and then using it to design your own plane — and hoping you win either way.
Saved answer · last researched 15 Nov 2026